Back to Search Start Over

Novel variants in KAT6B spectrum of disorders expand our knowledge of clinical manifestations and molecular mechanisms

Authors :
Megan Yabumoto
Jessica Kianmahd
Meghna Singh
Maria F. Palafox
Angela Wei
Kathryn Elliott
Dana H. Goodloe
S. Joy Dean
Catherine Gooch
Brianna K. Murray
Erin Swartz
Samantha A. Schrier Vergano
Meghan C. Towne
Kimberly Nugent
Elizabeth R. Roeder
Christina Kresge
Beth A. Pletcher
Katheryn Grand
John M. Graham Jr.
Ryan Gates
Natalia Gomez‐Ospina
Subhadra Ramanathan
Robin Dawn Clark
Kimberly Glaser
Paul J. Benke
Julie S. Cohen
Ali Fatemi
Weiyi Mu
Kristin W. Baranano
Jill A. Madden
Cynthia S. Gubbels
Timothy W. Yu
Pankaj B. Agrawal
Mary‐Kathryn Chambers
Chanika Phornphutkul
John A. Pugh
Kate A. Tauber
Svetlana Azova
Jessica R. Smith
Anne O’Donnell‐Luria
Hannah Medsker
Siddharth Srivastava
Deborah Krakow
Daniela N. Schweitzer
Valerie A. Arboleda
Source :
Molecular Genetics & Genomic Medicine, Vol 9, Iss 10, Pp n/a-n/a (2021)
Publication Year :
2021
Publisher :
Wiley, 2021.

Abstract

Abstract The phenotypic variability associated with pathogenic variants in Lysine Acetyltransferase 6B (KAT6B, a.k.a. MORF, MYST4) results in several interrelated syndromes including Say‐Barber‐Biesecker‐Young‐Simpson Syndrome and Genitopatellar Syndrome. Here we present 20 new cases representing 10 novel KAT6B variants. These patients exhibit a range of clinical phenotypes including intellectual disability, mobility and language difficulties, craniofacial dysmorphology, and skeletal anomalies. Given the range of features previously described for KAT6B‐related syndromes, we have identified additional phenotypes including concern for keratoconus, sensitivity to light or noise, recurring infections, and fractures in greater numbers than previously reported. We surveyed clinicians to qualitatively assess the ways families engage with genetic counselors upon diagnosis. We found that 56% (10/18) of individuals receive diagnoses before the age of 2 years (median age = 1.96 years), making it challenging to address future complications with limited accessible information and vast phenotypic severity. We used CRISPR to introduce truncating variants into the KAT6B gene in model cell lines and performed chromatin accessibility and transcriptome sequencing to identify key dysregulated pathways. This study expands the clinical spectrum and addresses the challenges to management and genetic counseling for patients with KAT6B‐related disorders.

Details

Language :
English
ISSN :
23249269
Volume :
9
Issue :
10
Database :
Directory of Open Access Journals
Journal :
Molecular Genetics & Genomic Medicine
Publication Type :
Academic Journal
Accession number :
edsdoj.beed8cf5cfdc460cbcfd56990a49d6fd
Document Type :
article
Full Text :
https://doi.org/10.1002/mgg3.1809